CD8A and neoplasm: To further evaluate the contribution of Jarid2 in CD8+ T cell antitumor immunity we transferred pmel-1 Jarid2−/− CD8+ T cells into tumor-bearing mice in conjunction with gp100-VV and interleukin-2 (IL-2) administration.